目的分析血清脑钠肽、降钙素原变化与心力衰竭患者纽约心脏病协会(New York Heart Association,NYHA)分级的相关性。方法选取2019年5月—2023年2月云南省玉溪市第二人民医院收治的97例心力衰竭患者为研究对象,所有患者都进行NYHA心功能...目的分析血清脑钠肽、降钙素原变化与心力衰竭患者纽约心脏病协会(New York Heart Association,NYHA)分级的相关性。方法选取2019年5月—2023年2月云南省玉溪市第二人民医院收治的97例心力衰竭患者为研究对象,所有患者都进行NYHA心功能分级后分为3组,心功能Ⅱ级57例(Ⅱ级组),心功能Ⅲ级28例(Ⅲ级组),心功能Ⅳ级12例(Ⅳ级组),检测3组血清脑钠肽、降钙素原含量并进行相关性分析。结果随着NYHA分级的增加,患者的左室射血分数明显降低,左室舒张末期内径明显升高,差异有统计学意义(P均<0.05)。随着NYHA分级的增加,患者的血清脑钠肽、降钙素原含量明显升高,差异有统计学意义(P均<0.05)。Spearman分析显示NYHA分级与血清脑钠肽、降钙素原含量、左室射血分数、左室舒张末期内径存在相关性(r=0.714、0.746、-0.788、0.692,P均<0.05)。结论心力衰竭患者多伴随有血清脑钠肽、降钙素原的高表达,与患者的NYHA分级存在相关性,可作为判断患者病情的重要依据。展开更多
目的探讨右心室舒张末期内径(RVED)与左心室舒张末期内径(LVED)的比值(RVED/LVED)对肺栓塞的诊断价值。方法回顾性分析深圳大学第一附属医院于2016年6月至2019年6月疑似肺栓塞并行CT肺动脉造影(CTPA)患者120例,将60例肺栓塞患者纳入肺...目的探讨右心室舒张末期内径(RVED)与左心室舒张末期内径(LVED)的比值(RVED/LVED)对肺栓塞的诊断价值。方法回顾性分析深圳大学第一附属医院于2016年6月至2019年6月疑似肺栓塞并行CT肺动脉造影(CTPA)患者120例,将60例肺栓塞患者纳入肺栓塞组,60例非肺栓塞患者为对照组。根据RVED/LVED由小到大分为3组(Tertile 1组:RVED/LVED<0.48、Tertile 2组:RVED/LVED:0.48~0.55、Tertile 3组:RVED/LVED≥0.56)。对3组肺栓塞发生率进行趋势性检验分析,应用多因素Logistic回归分析建立RVED/LVED预测肺栓塞的回归模型,通过受试者工作特征曲线分析预测模型对肺栓塞的诊断效能。结果肺栓塞组的RVED/LVED高于对照组(0.55±0.08 vs.0.50±0.06,P<0.001)。Tertile1组、Tertile2组、Tertile3组肺栓塞的发生率呈递增趋势(分别为30.8%、51.2%、67.5%,P for trend=0.001)。RVED/LVED为预测肺栓塞的独立影响因素,对比Tertle1组,Tertle2组与Tertle3组发生肺栓塞的风险比分别为3.690~5.216(P均<0.05)和5.673~9.627(P均<0.05),并呈趋势性增加(P for trend<0.05)。RVED/LVED与D-二聚体诊断肺栓塞的曲线下面积(AUC)分别为0.702、0.708,含RVED/LVED肺栓塞诊断模型可增加AUC 0.034(P=0.04)。结论RVED/LVED对肺栓塞的诊断具有一定的临床价值,结合危险因素及临床指标建立模型对肺栓塞的诊断效能更高。展开更多
[Objectives] To make a systematic evaluation on the therapeutic efficacy and safety of Yiqi Huoxue traditional Chinese drugs combined with western medicine in treatment of coronary heart disease( CHD) after coronary r...[Objectives] To make a systematic evaluation on the therapeutic efficacy and safety of Yiqi Huoxue traditional Chinese drugs combined with western medicine in treatment of coronary heart disease( CHD) after coronary revascularization. [Methods] The literatures were retrieved from China Knowledge Infrastructure( CNKI),Chinese science and technology journal full-text database( VIP database,VIP),Wanfang Data,the Chinese biomedical Database,Pub Med,Embase,and the Cochrane Library. The retrieval time was set to the creation of the database to January 2017. The randomized controlled trial( RCT) was conducted on the comparison between Yiqi Huoxue Chinese drugs combined with western medicine and the western medicine alone in the treatment of CHD after coronary revascularization. The literature information was extracted and the methodological quality of the included literature was evaluated according to the bias risk assessment tool developed by the Cochrane Collaboration. Meta-analysis was performed with the aid of Rev Man 5. 3 software. Coronary artery restenosis rate,angina pectoris treatment efficiency,left ventricular ejection fraction( LVEF),left ventricular end-diastolic volume( LVEDV),B-type natriuretic peptide( BNP),6-minute walk test( 6 MWT),and adverse reactions were analyzed. [Results] A total of 29 articles were included,a total of2 518 patients,the literature quality was low. Meta-analysis results showed that compared with the treatment by western medicine alone,Yiqi Huoxue Chinese drugs combined with western medicine could further reduce coronary restenosis rate[RR = 0. 45,95% CI( 0. 34,0. 60),P <0. 000 01],improve the angina pectoris treatment efficiency[RR = 1. 13,95% CI( 1. 05,1. 21),P = 0. 000 5],raise LVEF[WMD = 4. 25,95% CI( 3. 46,5. 04),P < 0. 000 01],reduce LVEDV[WMD =-10. 41,95% CI(-17. 88,-2. 95),P = 0. 006],decrease the plasma BNP level[WMD =-32. 32,95% CI(-44. 92,-19. 72),P < 0. 000 01],and increase 6 MWT distance(WMD = 62. 25,95% CI( 21. 71,102. 78),P = 0. 003)[Conclusions]Yiqi Huoxue Chinese drugs combined with western medicine can alleviate the symptoms of angina pectoris,reduce the rate of coronary restenosis,improve heart function and improve exercise capacity,thereby improving clinical efficacy in patients with CHD after coronary revascularization.展开更多
文摘目的分析血清脑钠肽、降钙素原变化与心力衰竭患者纽约心脏病协会(New York Heart Association,NYHA)分级的相关性。方法选取2019年5月—2023年2月云南省玉溪市第二人民医院收治的97例心力衰竭患者为研究对象,所有患者都进行NYHA心功能分级后分为3组,心功能Ⅱ级57例(Ⅱ级组),心功能Ⅲ级28例(Ⅲ级组),心功能Ⅳ级12例(Ⅳ级组),检测3组血清脑钠肽、降钙素原含量并进行相关性分析。结果随着NYHA分级的增加,患者的左室射血分数明显降低,左室舒张末期内径明显升高,差异有统计学意义(P均<0.05)。随着NYHA分级的增加,患者的血清脑钠肽、降钙素原含量明显升高,差异有统计学意义(P均<0.05)。Spearman分析显示NYHA分级与血清脑钠肽、降钙素原含量、左室射血分数、左室舒张末期内径存在相关性(r=0.714、0.746、-0.788、0.692,P均<0.05)。结论心力衰竭患者多伴随有血清脑钠肽、降钙素原的高表达,与患者的NYHA分级存在相关性,可作为判断患者病情的重要依据。
文摘目的探讨右心室舒张末期内径(RVED)与左心室舒张末期内径(LVED)的比值(RVED/LVED)对肺栓塞的诊断价值。方法回顾性分析深圳大学第一附属医院于2016年6月至2019年6月疑似肺栓塞并行CT肺动脉造影(CTPA)患者120例,将60例肺栓塞患者纳入肺栓塞组,60例非肺栓塞患者为对照组。根据RVED/LVED由小到大分为3组(Tertile 1组:RVED/LVED<0.48、Tertile 2组:RVED/LVED:0.48~0.55、Tertile 3组:RVED/LVED≥0.56)。对3组肺栓塞发生率进行趋势性检验分析,应用多因素Logistic回归分析建立RVED/LVED预测肺栓塞的回归模型,通过受试者工作特征曲线分析预测模型对肺栓塞的诊断效能。结果肺栓塞组的RVED/LVED高于对照组(0.55±0.08 vs.0.50±0.06,P<0.001)。Tertile1组、Tertile2组、Tertile3组肺栓塞的发生率呈递增趋势(分别为30.8%、51.2%、67.5%,P for trend=0.001)。RVED/LVED为预测肺栓塞的独立影响因素,对比Tertle1组,Tertle2组与Tertle3组发生肺栓塞的风险比分别为3.690~5.216(P均<0.05)和5.673~9.627(P均<0.05),并呈趋势性增加(P for trend<0.05)。RVED/LVED与D-二聚体诊断肺栓塞的曲线下面积(AUC)分别为0.702、0.708,含RVED/LVED肺栓塞诊断模型可增加AUC 0.034(P=0.04)。结论RVED/LVED对肺栓塞的诊断具有一定的临床价值,结合危险因素及临床指标建立模型对肺栓塞的诊断效能更高。
基金Supported by Project of National Natural Science Foundation of China(81460675)
文摘[Objectives] To make a systematic evaluation on the therapeutic efficacy and safety of Yiqi Huoxue traditional Chinese drugs combined with western medicine in treatment of coronary heart disease( CHD) after coronary revascularization. [Methods] The literatures were retrieved from China Knowledge Infrastructure( CNKI),Chinese science and technology journal full-text database( VIP database,VIP),Wanfang Data,the Chinese biomedical Database,Pub Med,Embase,and the Cochrane Library. The retrieval time was set to the creation of the database to January 2017. The randomized controlled trial( RCT) was conducted on the comparison between Yiqi Huoxue Chinese drugs combined with western medicine and the western medicine alone in the treatment of CHD after coronary revascularization. The literature information was extracted and the methodological quality of the included literature was evaluated according to the bias risk assessment tool developed by the Cochrane Collaboration. Meta-analysis was performed with the aid of Rev Man 5. 3 software. Coronary artery restenosis rate,angina pectoris treatment efficiency,left ventricular ejection fraction( LVEF),left ventricular end-diastolic volume( LVEDV),B-type natriuretic peptide( BNP),6-minute walk test( 6 MWT),and adverse reactions were analyzed. [Results] A total of 29 articles were included,a total of2 518 patients,the literature quality was low. Meta-analysis results showed that compared with the treatment by western medicine alone,Yiqi Huoxue Chinese drugs combined with western medicine could further reduce coronary restenosis rate[RR = 0. 45,95% CI( 0. 34,0. 60),P <0. 000 01],improve the angina pectoris treatment efficiency[RR = 1. 13,95% CI( 1. 05,1. 21),P = 0. 000 5],raise LVEF[WMD = 4. 25,95% CI( 3. 46,5. 04),P < 0. 000 01],reduce LVEDV[WMD =-10. 41,95% CI(-17. 88,-2. 95),P = 0. 006],decrease the plasma BNP level[WMD =-32. 32,95% CI(-44. 92,-19. 72),P < 0. 000 01],and increase 6 MWT distance(WMD = 62. 25,95% CI( 21. 71,102. 78),P = 0. 003)[Conclusions]Yiqi Huoxue Chinese drugs combined with western medicine can alleviate the symptoms of angina pectoris,reduce the rate of coronary restenosis,improve heart function and improve exercise capacity,thereby improving clinical efficacy in patients with CHD after coronary revascularization.
